The choice of antiplatelet therapy among Asian populations for the treatment of acute
coronary syndrome (ACS) is complicated owing to the high prevalence of cytochrome P450 …

Background: The present study aimed to determine the cost-effectiveness of ticagrelor
compared with clopidogrel in Iranian patients with acute coronary syndrome (ACS) …

Background Person-centred care has been shown to be cost-effective compared to usual
care for several diseases, including acute coronary syndrome, in a short-term time …

Aim: This study aimed to evaluate the cost–effectiveness of CYP2C19 loss-of-function (LOF)
allele-guided antiplatelet therapy compared with the universal use of clopidogrel or …

Background Obesity is a disease associated with high direct medical costs and high indirect
costs resulting from productivity loss. The high prevalence of obesity generates the need for …

BACKGROUND: Poor health outcomes after percutaneous coronary intervention (PCI) in
elderly patients is an area of concern among policymakers and administrators. In an effort to …

Abstract Introduction The PLATelet inhibition and patient Outcomes (PLATO) trial
(NCT00391872) demonstrated that ticagrelor compared to clopidogrel significantly reduced …

Background Outcomes-based agreements (OBA) are performance-based risk-sharing
agreements between manufacturers and payers which provide the opportunity for collection …

Antiplatelet agents represent a cornerstone in the management of patients at increased
cardiovascular risk. Essential hypertension is considered a major public health problem …

Ревматоидный артрит (РА) аутоиммунное заболевание, которому присущи
сравнительно высокая распространённость среди трудоспособного населения …